ClinicalTrials.gg
CompletedNCT02259231Updated Jun 4, 2025Results posted

RTA 408 Capsules in Patients With Melanoma - REVEAL

A Phase 1/2 interventional study of Omaveloxolone Capsules (2.5 mg/capsule) and Ipilimumab (3 mg/kg) in Melanoma, Unresectable (Stage III) Melanoma and Metastatic (Stage IV) Melanoma, sponsored by Biogen. Completed at 10 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-04.

Sponsored by Biogen · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
41
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 2,049 studies in Melanoma with a site in United States — 243 open to participants now, 440 under way, 32 of them phase 3. Melanoma · United States.

Enrollment
808th of 1,749
41 · median 37
Started
2014
with 80 others
Phase 1/2
287 of 2,049
51 open now
Registered
1,035th of 2,049
by date

Among the 2,049 studies in Melanoma with a site in United States, this one is the 808th largest by enrollment of the 1,749 interventional ones that give a count, is one of 81 that started in 2014, is one of 287 in phase 1/2, and was the 1,035th registered.

Melanoma

3,373 studies on the registry are indexed under Melanoma; 580 are open to participants now.

Browse Melanoma studies →

Open to participants now

243 of the 2,049 studies in Melanoma with a site in United States are open now. Recruiting first, the newest first:

238 more — sign in →

All 243 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 468 Melanoma studies recruiting now, 381 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,049 studies in Melanoma with a site in United States, or all of them as a file.
02

Study summary

Malignant melanoma is a leading cause of death from cutaneous malignancies, accounting for approximately three-fourths of all skin cancer deaths. For metastatic or unresectable melanomas, standard treatment options include immune checkpoint inhibitors (e.g., ipilimumab and nivolumab) and other therapies, however, approved therapies are rarely curative.

It is now well accepted that tumors are able to evade detection and eradication by the immune system, even though many tumor types, particularly melanoma, are capable of eliciting a strong immune response (Swann, 2007). Substantial mechanistic work in recent years has revealed the key role of myeloid-derived suppressor cells (MDSCs) in masking cancer cells from the immune system, promoting both tumor progression and resistance to cancer immunotherapy. The immune-suppressive effect of MDSCs is dependent on the production of reactive oxygen species (ROS) and reactive nitrogen species (RNS). High levels of these reactive molecules and their by-products, such as nitrotyrosine, have been correlated with poor clinical outcomes in melanoma. Currently available melanoma therapies do not target MDSCs.

In animals, RTA 408 significantly reduces tumor nitrotyrosine burden, inhibits the activity of MDSCs, and augments T-cell anticancer activity at relevant doses. Thus, through inhibition of MDSC activity and suppression of tumor ROS/RNS, RTA 408 may work in combination with T-cell-activating therapeutics such as ipilimumab to enhance the natural immune anticancer response. RTA 408 also has direct anticancer effects via inhibition of NF-kappa B. Chronic activation of NF-kappa B is associated with tumor progression, metastasis, and resistance to therapy.

This proposed study is designed to assess the safety, efficacy, pharmacodynamics, and pharmacokinetics of omaveloxolone (RTA 408) in combination with ipilimumab or nivolumab in patients with unresectable or metastatic melanoma.

In this open-label, multicenter, dose-escalation, Phase 1b/2 study, patients who qualify will receive omaveloxolone (RTA 408) at the assigned dose level in combination with ipilimumab or nivolumab. Patients will receive omaveloxolone (RTA 408) orally once daily for 1 week prior to initiation of ipilimumab or nivolumab. For patients treated with ipilimumab , the run-in period will be followed by omaveloxolone (RTA 408) orally once daily in combination with ipilimumab administered at Weeks 1, 4, 7, and 10. After Week 10, patients will receive maintenance treatment with omaveloxolone (RTA 408) alone once daily. For patients treated with nivolumab, the run-in period will be followed by omaveloxolone (RTA 408) orally once daily in combination with nivolumab administered approximately every two weeks as clinically indicated. Each patient will continue at the assigned omaveloxolone (RTA 408) dose level until disease progression occurs, toxicity requiring discontinuation from study drug (i.e., RTA 408) is experienced, the patient has completed approximately 72 weeks of treatment, the patient is discontinued from the study drug for another reason, or the patient withdraws consent. Patients will return 4 weeks after omaveloxolone (RTA 408) treatment completion for a follow-up visit.

The starting omaveloxolone (RTA 408) dose level for the first dose-escalation cohort in this study has been selected based on available safety and pharmacodynamic data from a Phase 1 study of RTA 408 (NCT02029729). Subsequent cohorts will be enrolled at dose levels based on available safety and PD data from this study, but they will not be greater than 2-fold above the prior dose level.

Phase 1b (dose-escalation): In the phase 1b/2 portion of this study, 12 patients will be enrolled in each dose cohort, with six patients administered omaveloxolone (RTA 408) plus ipilimumab and the remaining six administered rTA 408 plus nivolumab. Subsequent cohorts will assess escalating the doses of omaveloxolone (RTA 408) administered in combination with ipilimumab or nivolumab. Dose escalation decisions will be based on ongoing review of all available safety information for enrolled patients.

Phase 2: The Phase 2 portion of the study may include separate expansion cohorts consisting of patients treated with either of the combination therapies. Each expansion cohort will include an additional 24 patients enrolled at the selected Phase 2 dose level to achieve a total of 30 patients at that omaveloxolone (RTA 408) dose in combination with ipilimumab or nivolumab.

03

Conditions studied

  • Melanoma
  • Unresectable (Stage III) Melanoma
  • Metastatic (Stage IV) Melanoma

Keywords

  • RTA 408
  • RTA 408 Capsules
  • Myeloid-derived suppressor cells (MDSDs)
  • iNOS
  • Melanoma
  • Checkpoint inhibitor
  • omaveloxolone
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Be ≥18 years of age;
  2. Have advanced, unresectable (Stage III) or (Stage IV) melanoma;
  3. Be eligible for commercial receipt of therapy to be used in this study in combination with RTA 408 (i.e., ipilimumab or nivolumab in the Phase 1b portion and nivolumab only in the Phase 2 portion);
  4. Have discontinued previous treatments for cancer;
  5. Have discontinued previous experimental therapies and antibodies at least 28 days prior to the Randomization Visit

Exclusion criteria

Exclusion Criteria:

  1. Have received prior treatment with therapy to be used in this study in combination with RTA 408 (i.e., ipilimumab or nivolumab) if enrolling in the Phase 2 portion of the study. This criterion does not apply to patients enrolling in the Phase 1b portion of the study.
  2. Have prior active within the previous 2 years;
  3. Have any active disease or a history of known or suspected autoimmune disease;
  4. History of that meet certain conditions;
  5. History of specific cardiovascular abnormalities;
  6. Have known active fungal, bacterial, and/or viral infection, including (HIV) or hepatitis virus (A,B, or C).
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
41 participants (actual)

Study arms

  • Experimental
    Omaveloxolone 5 mg & ipilimumab

    Omaveloxolone (RTA 408) capsules, Dose1 taken orally once daily for 168 weeks, plus ipilimumab (3 mg/kg) administered at weeks 1, 4, 7, and 10.

    Drug: Omaveloxolone Capsules (2.5 mg/capsule) · Drug: Ipilimumab (3 mg/kg)

  • Experimental
    Omaveloxolone 10 mg & ipilimumab

    Omaveloxolone (RTA 408) capsules, 10 mg taken orally once daily for 168 weeks, plus ipilimumab (3 mg/kg) administered at weeks 1, 4, 7, and 10.

    Drug: Ipilimumab (3 mg/kg) · Drug: Omaveloxolone Capsules (10 mg/capsule)

  • Experimental
    Omaveloxolone 5 mg & nivolumab

    Omaveloxolone (RTA 408) capsules, 5 mg taken orally once daily for 168 weeks, plus nivolumab (240 mg) administered every two weeks as clinically indicated.

    Drug: Omaveloxolone Capsules (2.5 mg/capsule) · Drug: Nivolumab (240 mg)

  • Experimental
    Omaveloxolone 10 mg & nivolumab

    Omaveloxolone (RTA 408) capsules, 10 mg taken orally once daily for 168 weeks, plus nivolumab (240 mg) administered every two weeks as clinically indicated.

    Drug: Nivolumab (240 mg) · Drug: Omaveloxolone Capsules (10 mg/capsule)

  • Experimental
    Omaveloxolone 20 mg & nivolumab

    Omaveloxolone (RTA 408) capsules, 20 mg taken orally once daily for 168 weeks, plus nivolumab (240 mg) administered every two weeks as clinically indicated.

    Drug: Nivolumab (240 mg) · Drug: Omaveloxolone Capsules (10 mg/capsule)

  • Experimental
    Omaveloxolone 100 mg & nivolumab

    Omaveloxolone (RTA 408) capsules, 100 mg taken orally once daily for 168 weeks, plus nivolumab (240 mg) administered every two weeks as clinically indicated.

    Drug: Nivolumab (240 mg) · Drug: Omaveloxolone Capsules (50 mg/capsule)

  • Experimental
    Omaveloxolone 150 mg & nivolumab

    Omaveloxolone (RTA 408) capsules, 150 mg taken orally once daily for 168 weeks, plus nivolumab (240 mg) administered every two weeks as clinically indicated.

    Drug: Nivolumab (240 mg) · Drug: Omaveloxolone Capsules (50 mg/capsule)

Interventions

  • DrugOmaveloxolone Capsules (2.5 mg/capsule)

    Drug page: Omaveloxolone

    Capsules containing 2.5 mg of omaveloxolone per capsule to the dosage indicated in the Arm Label

    Also known as: RTA 408 Capsules (2.5 mg/capsule)

  • DrugIpilimumab (3 mg/kg)

    Drug page: Ipilimumab

    Sterile solution containing ipilimumab to be delivered intravenously at 3mg/kg

    Also known as: Yervoy

  • Sterile solution containing nivolumab to be delivered intravenously at 240 mg

    Also known as: Opdivo

  • DrugOmaveloxolone Capsules (10 mg/capsule)

    Drug page: Omaveloxolone

    Capsules containing 10 mg of omaveloxolone per capsule to the dosage indicated in the Arm Label

    Also known as: RTA 408 Capsules (10 mg/capsule)

  • DrugOmaveloxolone Capsules (50 mg/capsule)

    Drug page: Omaveloxolone

    Capsules containing 50 mg of omaveloxolone per capsule to the dosage indicated in the Arm Label

    Also known as: RTA 408 Capsules (50 mg/capsule)

06

What researchers measure

Primary outcomes

  1. Measure of Efficacy of the Phase 2 Dose of RTA 408 in Combination With Nivolumab Using Overall Response Rate (ORR; Complete Plus Partial Responses) According to RECIST Version 1.1 Criteria

    Best overall response rate (ORR) is defined as the proportion of patients with complete or partial tumor size reduction according to RECIST v1.1 criteria. Stable disease is not a component of ORR. Complete response: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. Partial reduction: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. The first occurrence of a response is considered an unconfirmed response. A CR or PR which persists to the next tumor burden assessment is then considered a confirmed response. Confirmed plus unconfirmed best overall response are presented. A subject may be counted twice if best unconfirmed response and best confirmed response are different.

    Time frame: From enrollment up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab

07

Results

Posted Jun 24, 2021

Participant flow

Participant flow — Overall Study
MilestoneOmaveloxolone 5 mg & IpilimumabOmaveloxolone 10 mg & IpilimumabOmaveloxolone 5 mg & NivolumabOmaveloxolone 10 mg & NivolumabOmaveloxolone 20 mg & NivolumabOmaveloxolone 100 mg & NivolumabOmaveloxolone 150 mg & Nivolumab
Started6666665
Completed0000000
Not completed6666665
Withdrew: Adverse event1120000
Withdrew: Progressive disease4545454
Withdrew: Sponsor termination of study1001211

Outcome measures

PrimaryMeasure of Efficacy of the Phase 2 Dose of RTA 408 in Combination With Nivolumab Using Overall Response Rate (ORR; Complete Plus Partial Responses) According to RECIST Version 1.1 Criteria

Best overall response rate (ORR) is defined as the proportion of patients with complete or partial tumor size reduction according to RECIST v1.1 criteria. Stable disease is not a component of ORR. Complete response: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. Partial reduction: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. The first occurrence of a response is considered an unconfirmed response. A CR or PR which persists to the next tumor burden assessment is then considered a confirmed response. Confirmed plus unconfirmed best overall response are presented. A subject may be counted twice if best unconfirmed response and best confirmed response are different.

Time frame:
From enrollment up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab
Reported as:
Count of participants · Participants
Measure of Efficacy of the Phase 2 Dose of RTA 408 in Combination With Nivolumab Using Overall Response Rate (ORR; Complete Plus Partial Responses) According to RECIST Version 1.1 Criteria
ParticipantsOmaveloxolone 5 mg & IpilimumabOmaveloxolone 10 mg & IpilimumabOmaveloxolone 5 mg & NivolumabOmaveloxolone 10 mg & NivolumabOmaveloxolone 20 mg & NivolumabOmaveloxolone 100 mg & NivolumabOmaveloxolone 150 mg & Nivolumab
Best Overall Responses6052334
Progressive Disease3030132
Stable Disease1011111
Partial Response3002202
Complete Response0010100

Adverse events

Collected over Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab.. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Omaveloxolone 5 mg & Ipilimumab0/6 (0%)2/6 (33.3%)6/6 (100%)
Omaveloxolone 10 mg & Ipilimumab0/6 (0%)2/6 (33.3%)6/6 (100%)
Omaveloxolone 5 mg & Nivolumab1/6 (16.7%)1/6 (16.7%)6/6 (100%)
Omaveloxolone 10 mg & Nivolumab1/6 (16.7%)3/6 (50%)6/6 (100%)
Omaveloxolone 20 mg & Nivolumab2/6 (33.3%)2/6 (33.3%)6/6 (100%)
Omaveloxolone 100 mg & Nivolumab0/6 (0%)2/6 (33.3%)6/6 (100%)
Omaveloxolone 150 mg & Nivolumab1/5 (20%)2/5 (40%)5/5 (100%)
Most frequent serious events
Showing 10 of 19
Most frequent serious events
EventOmaveloxolone 5 mg & IpilimumabOmaveloxolone 10 mg & IpilimumabOmaveloxolone 5 mg & NivolumabOmaveloxolone 10 mg & NivolumabOmaveloxolone 20 mg & NivolumabOmaveloxolone 100 mg & NivolumabOmaveloxolone 150 mg & Nivolumab
Disease progressionGeneral disorders0/60/60/61/62/60/60/5
Soft tissue infectionInfections and infestations1/60/60/60/60/60/61/5
Transient ischaemic attackNervous system disorders0/60/60/60/60/60/61/5
Neoplasm malignantNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/60/60/60/60/60/61/5
Lung InfectionInfections and infestations1/60/60/60/60/60/60/5
Clostridial infectionInfections and infestations0/60/60/60/60/61/60/5
ColitisGastrointestinal disorders0/61/60/60/60/60/60/5
Abdominal painGastrointestinal disorders0/60/60/60/60/61/60/5
Oesophageal disorderGastrointestinal disorders0/60/60/61/60/60/60/5
Abdominal pain lowerGastrointestinal disorders0/60/60/61/60/60/60/5
Most frequent other events
Showing 10 of 229
Most frequent other events
EventOmaveloxolone 5 mg & IpilimumabOmaveloxolone 10 mg & IpilimumabOmaveloxolone 5 mg & NivolumabOmaveloxolone 10 mg & NivolumabOmaveloxolone 20 mg & NivolumabOmaveloxolone 100 mg & NivolumabOmaveloxolone 150 mg & Nivolumab
FatigueGeneral disorders5/65/65/61/66/61/63/5
DiarrhoeaGastrointestinal disorders3/63/61/61/62/64/62/5
NauseaGastrointestinal disorders4/64/64/61/62/64/60/5
PruritusSkin and subcutaneous tissue disorders4/63/62/61/62/60/60/5
Nasal congestionRespiratory, thoracic and mediastinal disorders0/62/62/60/61/61/63/5
Abdominal painGastrointestinal disorders0/63/62/62/61/61/60/5
ConstipationGastrointestinal disorders1/62/63/63/63/60/61/5
Upper respiratory tract infectionInfections and infestations3/60/61/60/60/62/61/5
FallInjury, poisoning and procedural complications0/60/61/63/60/60/61/5
Alanine aminotransferase increasedInvestigations3/62/62/61/60/61/61/5

Baseline characteristics

Age, Continuous
Age, Continuous(years)Omaveloxolone 5 mg & IpilimumabOmaveloxolone 10 mg & IpilimumabOmaveloxolone 5 mg & NivolumabOmaveloxolone 10 mg & NivolumabOmaveloxolone 20 mg & NivolumabOmaveloxolone 100 mg & NivolumabOmaveloxolone 150 mg & NivolumabTotal
Mean59.17 ± 18.71353.5 ± 8.2468.33 ± 12.4251.67 ± 11.2960.5 ± 13.88265 ± 7.32165 ± 5.95860.3 ± 12.49
Sex: Female, Male
Sex: Female, Male(Participants)Omaveloxolone 5 mg & IpilimumabOmaveloxolone 10 mg & IpilimumabOmaveloxolone 5 mg & NivolumabOmaveloxolone 10 mg & NivolumabOmaveloxolone 20 mg & NivolumabOmaveloxolone 100 mg & NivolumabOmaveloxolone 150 mg & NivolumabTotal
Female323044117
Male343622424
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Omaveloxolone 5 mg & IpilimumabOmaveloxolone 10 mg & IpilimumabOmaveloxolone 5 mg & NivolumabOmaveloxolone 10 mg & NivolumabOmaveloxolone 20 mg & NivolumabOmaveloxolone 100 mg & NivolumabOmaveloxolone 150 mg & NivolumabTotal
Hispanic or Latino00110002
Not Hispanic or Latino665566539
Unknown or Not Reported00000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Omaveloxolone 5 mg & IpilimumabOmaveloxolone 10 mg & IpilimumabOmaveloxolone 5 mg & NivolumabOmaveloxolone 10 mg & NivolumabOmaveloxolone 20 mg & NivolumabOmaveloxolone 100 mg & NivolumabOmaveloxolone 150 mg & NivolumabTotal
American Indian or Alaska Native00000000
Asian00000000
Native Hawaiian or Other Pacific Islander00000000
Black or African American00000000
White666666541
More than one race00000000
Unknown or Not Reported00000000
08

Study locations

10 sites
  • Southern Cancer Center
    Mobile, Alabama 36608, United States
  • Highlands Oncology Group
    Fayetteville, Arkansas 72703, United States
  • University of Colorado Cancer Center, Anschutz Cancer Pavilion
    Aurora, Colorado 80045, United States
  • Christiana Hospital Helen F. Graham Cancer Center
    Newark, Delaware 19713, United States
  • Goergetown-Lombardi Comprehensive Cancer Center
    Washington, District of Columbia 20007, United States
  • H. Lee Moffitt Cancer Center & Research Institute
    Tampa, Florida 33612, United States
  • Dana Farber Cancer Institute
    Boston, Massachusetts 02215, United States
  • Atlantic Melanoma Center
    Morristown, New Jersey 07960, United States
  • Duke Cancer Institute
    Durham, North Carolina 27710, United States
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on https://www.biogentrialtransparency.com/

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2014 to primary completion in May 2018, 42 months.

Results were first posted in Jun 2021, 3 years 1 month after primary completion. A results delay was requested in May 2019.

Of 135 industry-sponsored phase 1/2 interventional studies under Melanoma, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 84. This study's 42 months is below that.

Counting every sponsor, half of 220 studies reached it within 61 months; a quarter within 42 and three quarters within 85.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 3, 2014
First posted
Oct 8, 2014
StartActual
Oct 31, 2014
Primary completionActual
May 9, 2018
CompletionActual
Jul 23, 2018
Results delay requested
May 1, 2019
Results first posted
Jun 24, 2021
Last update
Jun 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02259231
Lead sponsor
Biogen
Responsible party
Sponsor
First posted
Oct 8, 2014
Start date
Oct 31, 2014
Primary completion
May 9, 2018
Completion
Jul 23, 2018
Results posted
Jun 24, 2021
Last update
Jun 4, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Omaveloxolone

Start the discussion